Tenet Healthcare Corporation (THC) has been one of the strongest performers in the hospital and ambulatory-care space, and its stock now trades near $266 — not far below the Wall Street price targets that were raised in a wave after its latest quarterly report. Whether the shares can reach roughly $295 depends less on the direction of analyst opinion and more on whether Tenet can keep delivering the earnings and cash-flow growth that have driven a multi-year re-rating.
Tenet Healthcare is broadly liked on the Street, with a "Moderate Buy" consensus and no sell ratings among the firms actively covering the name. Current individual targets cluster tightly: Guggenheim recently lifted its target to $307 from $283, while UBS ($308), Piper Sandler ($308), Cantor Fitzgerald ($309), and Leerink Partners ($309) sit at the high end. Goldman Sachs ($305), BofA ($295), Mizuho ($290), Truist ($290), Stephens ($285), Raymond James ($285), RBC Capital ($283), Wells Fargo ($281), Baird ($280), and Morgan Stanley ($274) form the middle, while Barclays ($271), BMO Capital ($265), and KeyBanc ($225) sit lower.
Because the overall average of these targets — near $286 — is only about 7% above the latest price, it does not clear a meaningful 10% threshold. The $295 central target is therefore calculated from only the targets above the current price, which average about $293 and round to $295. The full range of roughly $225 to $309 shows real disagreement about how much upside remains after the stock's strong run.
With the shares near $266, reaching $295 requires a gain of roughly $29, or about 11% — a modest move by this stock's standards, given a 52-week range of $157.58 to $283.05 and a beta of 1.20. Tenet trades at about 10.5 times trailing earnings, well below the broader healthcare sector, reflecting a persistent discount for balance-sheet and policy risk rather than a lack of earnings momentum.
The path toward the target runs through continued execution: same-facility volume growth in high-acuity services, expanding ambulatory surgical center (ASC) volumes at USPI, cost discipline, and share repurchases. Management lifted its 2026 outlook after second-quarter results, citing strength across both the hospital and ambulatory segments.
Tenet's most recent quarter was a clear beat: EPS (earnings per share) of $6.12 versus a $4.26 consensus estimate, with revenue of $6.04 billion, up 6.8% year over year. The company subsequently raised its full-year 2026 guidance for adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) and free cash flow, with EPS guidance of $20.30 to $21.69.
Analysts consistently cite the shift toward USPI's ambulatory surgery centers, high-acuity procedure growth, cost-efficiency gains, and capital returns as reasons for constructive views. Several firms raised targets in late July and again in October, a sign that estimate revisions are still moving upward.
The principal risk is that much of the good news is already priced in: after a 90-day gain of more than 30% at one point, the stock trades only modestly below the average target, leaving little room for multiple expansion. Policy remains a live concern, as uncertainty over ACA subsidy extensions and payor mix could pressure margins. Tenet also carries meaningful leverage (a debt-to-equity ratio near 2.0), and recent insider selling adds a note of caution. A guidance miss or softening hospital volumes could compress the multiple quickly.
Technically, the shares pulled back from their August high near $283, which now acts as the first significant resistance zone on the way to $295. The 50-day moving average around $264 and the psychologically important $260 level provide nearby support, while the 200-day moving average near $219 marks the longer-term trend line. A decisive move above $283 would open the path toward the $300 psychological level and the $295 target, while a failure to hold $260 could signal a deeper consolidation.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms set them on different schedules and the stock's rapid rally has compressed many targets toward the current price. The next catalyst is the third-quarter report, scheduled for October 29, 2026. Investors should watch same-facility volume and pricing trends, USPI case growth, 2027 guidance, the pace of buybacks, and any Washington developments on ACA subsidies and healthcare reimbursement.
For traders monitoring Tenet and the broader healthcare complex, Tickeron's AI Daily Buy/Sell Signals offer a data-driven complement to fundamental research. The platform uses artificial intelligence to continuously scan thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, monitor existing positions, and identify shifting trends more efficiently than manual chart review alone.
The question of whether THC can reach $295 is fundamentally about execution rather than valuation expansion. The target is a calculated average of the analyst targets above the current price, requiring about an 11% move. Ambulatory growth, high-acuity momentum, and raised guidance support the case, while policy risk, leverage, and a valuation that has already absorbed much of the optimism are the main obstacles. With the next earnings report days away, the stock's direction toward — or away from — $295 will likely be determined by whether the operating story keeps outperforming expectations.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, THC has been loosely correlated with HCA. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if THC jumps, then HCA could also see price increases.
| Ticker / NAME | Correlation To THC | 1D Price Change % |
|---|---|---|
| THC | 100% | -1.09% |
| Hospital/Nursing Management industry (48 stocks) | 27% Poorly correlated | -3.65% |